Compare FNRN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNRN | VNDA |
|---|---|---|
| Founded | 1910 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 301.1M |
| IPO Year | 2000 | 2005 |
| Metric | FNRN | VNDA |
|---|---|---|
| Price | $17.73 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 87.4K | ★ 702.7K |
| Earning Date | 07-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.42 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | $27.56 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $15.93 | $4.27 |
| 52 Week High | $19.25 | $9.91 |
| Indicator | FNRN | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 31.21 |
| Support Level | $17.52 | $4.45 |
| Resistance Level | $17.88 | $5.37 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 80.51 | 6.55 |
First Northern Community Bancorp is a bank holding company for a community bank, First Northern Bank of Dixon. It conducts general banking activities, including collecting deposits and originating loans, and serves Solano, Yolo, Sacramento, Placer, El Dorado, and Contra Costa Counties. It offers a broad range of alternative investment products and services, equipment leasing, credit cards, merchant card processing, payroll services, and limited international banking services. The bank generates the majority of its revenue by providing various products and services to small and medium-sized businesses and individuals. including accepting demand, interest bearing transaction, savings, and time deposits, and making commercial, consumer, and real estate-related loans.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.